Shares Magazine
10.25p+0.75 (+7.89%)22 Nov 2024, 16:27
Jump to:
Belluscura PLC Fundamentals
| Company Name | Belluscura PLC | Last Updated | 2024-11-22 |
|---|---|---|---|
| Industry | Medical Devices | Sector | Healthcare |
| Shares in Issue | 168.408 m | Market Cap | £17.26 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -$0.14 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | 1.1576 | Cash Equity Ratio | 0.0472 |
| Quick Ratio | 2.0895 | Current Ratio | 3.25 |
| Price To Book Value | 1.1699 | ROCE | 0 |
Belluscura PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Belluscura PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | $323,815.00 | $399,641.00 | $324,959.00 |
| Intangible Assets | $9.99 m | $8.67 m | $6.72 m |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | $12.26 m | $9.07 m | $7.05 m |
| Stocks | $3.32 m | $8.43 m | $309,159.00 |
| Debtors | $4.22 m | $4.01 m | $2.54 m |
| Cash & Equivalents | $932,926.00 | $2.04 m | $15.89 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | $20.82 m | $23.60 m | $26.00 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | $3.07 m | $3.05 m | $1.08 m |
| Creditors after 1 year | $61,267.00 | $200,432.00 | $247,823.00 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | $3.13 m | $3.25 m | $1.33 m |
| Net assets | $17.69 m | $20.35 m | $24.67 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | $1.85 m | $1.66 m | $1.55 m |
| Share Premium | $37.66 m | $33.54 m | $26.19 m |
| Profit / Loss | -$18.52 m | -$8.15 m | -$5.21 m |
| Other Equity | $17.69 m | $20.35 m | $24.67 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | $17.69 m | $20.35 m | $24.67 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | $0.00 | $0.01 | $0.01 |
| Debt-to-Equity | $0.00 | $0.01 | $0.01 |
| Assets / Equity | 1.1576 | 1.1576 | 1.1576 |
| Cash / Equity | 0.0472 | 0.0472 | 0.0472 |
| EPS | -$0.14 | -$0.06 | -$0.06 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | -$9.13 m | -$14.91 m | -$6.99 m |
| Cashflow before financing | $3.38 m | -$7.62 m | $18.37 m |
| Increase in Cash | -$1.15 m | -$12.70 m | $15.58 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | $825,409.00 | $1.40 m | $420,316.00 |
| Cost of sales | $5.03 m | $1.94 m | $472,487.00 |
| Gross Profit | -$4.20 m | -$541,743.00 | -$52,171.00 |
| Operating Profit | -$17.69 m | -$8.13 m | -$5.19 m |
| Pre-Tax profit | -$18.52 m | -$8.15 m | -$5.21 m |
Belluscura PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The company has only one operating segment being the sale of oxygen concentrators in the United States. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments. |
| Latest Interim Date | 26 Sep 2024 |
| Latest Fiscal Year End Date | 27 Jun 2024 |
Belluscura PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2024-02-09 | Mr. Richard John Piper | Non-Executive Director |
| 2024-02-09 | Mr. Adam Reynolds | Non-Executive Director,Chairman |
| 2023-10-03 | Mr. Anthony Stephen Dyer | Executive Director,Chief Financial Officer and Company Secretary |
| 2024-07-04 | Mr. David John Poutney | Non-Executive Director |
| 2024-07-11 | Mr. Jonathan Satchell | Non-Executive Director |
| 2024-02-09 | Mr. Robert Rauker | Executive Director,Chief Executive Officer |
| 2023-10-24 | Dr. Patrick John Strollo Jr | Non-Executive Director |
| 2024-02-09 | Mr. Robert Sylvester Fary | Executive Director |
| 2024-07-19 | Mr. Simon Joseph Neicheril | Executive Director,Chief Financial Officer |
Belluscura PLC Contact Details
| Company Name | Belluscura PLC |
|---|---|
| Address | 15 Fetter Lane, London, EC4A 1BW |
| Telephone | +44 7814229686 |
| Website | https://www.belluscura.com |
Belluscura PLC Advisors
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Jd Sports Fashion PLC | 96.48 | 3.23 |
| Helios Towers PLC | 97.00 | 0.73 |
| Trainline PLC | 418.80 | 3.05 |
| Urban Logistics Reit PLC | 109.60 | 3.01 |
| Cmc Markets PLC | 271.25 | 2.75 |
| Anglo American PLC | 2,410.50 | 2.18 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Bridgepoint Group PLC | 318.80 | -4.72 |
| Dr. Martens PLC | 54.15 | -3.99 |
| Petershill Partners PLC | 235.00 | -2.89 |
| Bakkavor Group PLC | 126.35 | -2.81 |
| Sthree PLC | 337.01 | -2.60 |
| Hilton Food Group PLC | 898.50 | -2.34 |